Ron Long resigns from Medivir as Maris Hartmanis made CEO
This article was originally published in Scrip
Dr Maris Hartmanis, who joined Medivir on 1 September as deputy CEO and COO (scripintelligence.com, 1 September 2011), has been appointed the company's president and CEO. He will replace Ron Long who has been president and CEO of Medivir since 2009. Mr Long has resigned as CEO and a Medivir board member, following consultation with the board. Dr Hartmanis was appointed CEO of BioPhausia in 2010, a company which was recently acquired by Medivir.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.